Blueberry Therapeutics and LSTM are awarded an MRC Confidence in Concept grant to explore nano-formulations of Ceftriaxone for the treatment of Typhoid fever.

Dave Cook, Chief Scientific Officer at Blueberry said “We’re delighted to be working with the team at LSTM on this exciting project. Typhoid fever is a major human health issue and so exploring the potential application of our nano-formulations to improve antibiotic therapy is an important first step in improving treatment of the disease.”

The MRC Confidence in Concept (CiC) scheme provides funding to institutions to support the earliest stages of translational research projects. More details can be found using the link below

http://www.lstmed.ac.uk/research/institutional-funding/mrc-confidence-in-concept-fund-2015/mrc-cic-successful-applicants

Blueberry are delighted to welcome Mr. Andrew Kay to Blueberry Therapeutics as Chairman of the Board. Andrew brings more than 30 years of commercial and leadership experience in the pharmaceutical sector, latest as CEO of Algeta ASA. During Andrew’s leadership, Algeta’s lead product, Xofigo, was approved by the FDA and EMA for the treatment of bone metastases in castration resistant prostate cancer patients. In February 2014, Algeta was acquired by its partner Bayer AG for USD 2.9 billion. Andrew’s previous roles include Global Head of Marketing and Sales and a Member of the Healthcare Committee and Pharmaceutical Executive Committee at Novartis, and several other senior commercial positions in Europe and the USA with AstraZeneca, Eli Lilly, Sandoz and Boots.